217 related articles for article (PubMed ID: 19578651)
1. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.
Cerci JJ; Pracchia LF; Soares Junior J; Linardi Cda C; Meneghetti JC; Buccheri V
Clinics (Sao Paulo); 2009; 64(6):491-8. PubMed ID: 19578651
[TBL] [Abstract][Full Text] [Related]
2. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
[TBL] [Abstract][Full Text] [Related]
3. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
4. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
[TBL] [Abstract][Full Text] [Related]
5. Whole-Body Diffusion-Weighted MRI Compared to
Shapira-Zaltsberg G; Wilson N; Trejo Perez E; Abbott L; Dinning S; Kapoor C; Davila J; Smith B; Miller E
Can Assoc Radiol J; 2020 May; 71(2):217-225. PubMed ID: 32062992
[TBL] [Abstract][Full Text] [Related]
6. Staging in childhood lymphoma: differences between FDG-PET and CT.
Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C
Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
[TBL] [Abstract][Full Text] [Related]
7. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
8. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
Ömür Ö; Baran Y; Oral A; Ceylan Y
Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
[TBL] [Abstract][Full Text] [Related]
9. Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era.
Richardson SE; Sudak J; Warbey V; Ramsay A; McNamara CJ
Leuk Lymphoma; 2012 Mar; 53(3):381-5. PubMed ID: 21877882
[TBL] [Abstract][Full Text] [Related]
10. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
Hutchings M; Loft A; Hansen M; Pedersen LM; Berthelsen AK; Keiding S; D'Amore F; Boesen AM; Roemer L; Specht L
Haematologica; 2006 Apr; 91(4):482-9. PubMed ID: 16585015
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
Kandeel AA; Hussein M; Zidan L; Younis J; Edesa W; Alsayed Y
Nucl Med Commun; 2020 Mar; 41(3):269-279. PubMed ID: 31895758
[TBL] [Abstract][Full Text] [Related]
12. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
[TBL] [Abstract][Full Text] [Related]
13. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
[TBL] [Abstract][Full Text] [Related]
15. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
[TBL] [Abstract][Full Text] [Related]
16. Comparison of
Panebianco M; Bagni O; Cenfra N; Mecarocci S; Ortu La Barbera E; Filippi L; Codacci-Pisanelli G; Biondi T; Laghi A; Cimino G
Leuk Res; 2019 Jan; 76():48-52. PubMed ID: 30553980
[TBL] [Abstract][Full Text] [Related]
17. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
19. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
20. Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT.
Weiler-Sagie M; Kagna O; Dann EJ; Ben-Barak A; Israel O
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1133-40. PubMed ID: 24570095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
